• Print
  • Send to a friend
  • Comment (0)
  •  

P.E.I. research facility gets federal funding

Published on September 10, 2012
Published on September 10, 2012
Topics :
Delivra , National Research Council of Canada , NRC , Prince Edward Island , Canada , Charlottetown

Delivra Inc. today officially opened a new research facility on Prince Edward Island.

Gary Goodyear, minister of state for science and technology, announced an investment from the Government of Canada that will help the company to conduct research in its incubation space at the National Research Council of Canada (NRC) Industrial Partnership Facility in Charlottetown, develop working relationships with Prince Edward Island industries, aid in job creation, and expand the province’s export markets through its products.

He said Ottawa continues to focus on the top priorities of jobs, growth and long-term prosperity, and investing in innovative companies like Delivra Inc. is an effective way to meet the goals.

“The Government of Canada’s investment will help Delivra Inc. to establish its presence in Prince Edward Island, boost national innovation and break into major global markets, all of which will have a positive economic impact on the Atlantic Canadian economy,”  he said.

A news release says Delivra™ is a unique base compound that acts as an alternative drug delivery system. It safely penetrates deep through the skin to reach joints, muscles, and other tissues, and delivers active ingredients to areas that other topicals cannot reach.

The technology holds potential for different applications.  Delivra™ was developed by Dr. Joseph Gabriele, a Canadian university professor and molecular pharmacologist who discovered its properties while assisting his wife in dealing with chronic pain.

The Government of Canada, through ACOA’s Business Development Program, has invested a total of $220,000 to help Delivra Inc. open the new research facility on Prince Edward Island. This investment includes the purchasing of the new equipment, which is necessary for Delivra to conduct their research. 

“This vital funding will help us investigate new opportunities to combine Delivra™ with other medications that can only be taken orally or through injectibles today,” said Dr. Gabriele, who is also president and chief scientific officer of Delivra Inc.

“As a result of the government’s investment into Delivra Inc., many Canadians will one day be able to take their current medications in a safer topical format – getting the same benefit, but with fewer side effects.”

 

Submit a comment

Submit a comment (we keep all emails private)
Agreement

We ask that users remain courteous. You may not post insulting, discriminatory or inappropriate content, which may be removed at our discretion. We are not responsible for user content and opinions. Use of this site as well as content submission & ownership are governed by our Conditions of Use and Privacy Policy.

Member organizations should be non-profit in nature, and promote legal activities. Any organization found promoting illegal activities or commercial products or services will be deleted from the site.

I agree with these conditions.

Advertising

Newsletter

Please enter your email to receive our free newsletter

Subscribe to news alerts
loading...

Expert bloggers

Ride for Heart
Blogger
Heart and Stroke Foundation
Putting those unused gears into action
[Sponsored]

More bloggers here

The Guardian Twitter

Advertising